Neuroblastoma

The grounding supports a genetic contribution to neuroblastoma, with literature focusing on molecular signatures and genetic variations involved in its pathogenesis. It also notes that numerous genetic and genomic alterations and dysfunctional pathways drive disease onset, growth, progression, and resistance to therapy. No single causal exposure or definitive aetiology is specified in the supplied material.

Neuroblastoma develops from neural crest-derived cells in the sympathetic nervous system and shows characteristic histology of uniform round cells with hyperchromatic nuclei arranged in nests separated by fibrovascular septa. The literature grounding emphasizes genetic and genomic alterations, dysfunctional pathways, and phosphorylation-related mechanisms as contributors to tumor initiation, progression, and treatment resistance. The disease is also associated with opsoclonus-myoclonus syndrome.

The supplied grounding does not identify specific epidemiologic or environmental risk factors. It does indicate that genetic and genomic alterations are associated with the disease, but does not define these as patient-level risk factors. No additional risk factors are supported by the provided material.

The grounding supports treatment at the modality level as drug therapy and molecular targeting therapies, reflecting efforts to use targeted approaches against disease-driving pathways. Isotretinoin is co-studied, indicating a role for retinoid-based therapy in the literature, and monoclonal antibodies are also represented among co-studied entities. The supplied material does not support more specific standard treatment details beyond these broad categories.